BioNTech (BNTX) Scheduled to Post Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. BioNTech has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter last year, the business posted ($0.86) earnings per share. The company’s revenue for the quarter was down 23.3% on a year-over-year basis. On average, analysts expect BioNTech to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

BioNTech Stock Down 1.4 %

BioNTech stock opened at $111.48 on Friday. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The stock has a market cap of $26.51 billion, a PE ratio of -49.33 and a beta of 0.26. The stock’s fifty day moving average is $109.72 and its two-hundred day moving average is $95.77.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. HC Wainwright raised their price target on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Bank of America raised their price target on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. Five equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $135.54.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.